Conflict of interest No conflict of interest exists.
Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan
Article first published online: 9 MAR 2011
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 26, Issue 1, pages 59–65, January 2012
How to Cite
Chiang, Y.-Y. and Lin, H.-W. (2012), Association between psoriasis and chronic obstructive pulmonary disease: a population-based study in Taiwan. Journal of the European Academy of Dermatology and Venereology, 26: 59–65. doi: 10.1111/j.1468-3083.2011.04009.x
Funding sources The authors state that no funding sources.
- Issue published online: 15 DEC 2011
- Article first published online: 9 MAR 2011
- Received: 19 July 2010; Accepted: 27 January 2011
Background Psoriasis is regarded as a systemic inflammatory disease, having been linked in recent studies, to a wide range of systemic disorders. Previous studies have reported a positive correlation between psoriasis and chronic obstructive pulmonary disease (COPD); however, no studies have been conducted on an ethnic Chinese population.
Methods We conducted a population-based study, using a representative cohort from the National Health Insurance database in Taiwan, between 2004 and 2006. The risk of COPD was compared between patients with psoriasis and a matched reference cohort. This study included 2096 psoriasis patients and 8384 randomly selected controls.
Results After adjusting for sociodemographic characteristics and selected chronic diseases, the hazard ratio (HR) for COPD in psoriasis patients was 2.35 (95% confidence interval (CI): 1.42–3.89) compared with the control group in 18 months of follow-4 up. Men (HR = 2.38, 95% CI: 1.36–4.18) and patients with psoriasis over 50 years of age (HR = 2.19, 95% CI: 1.27–3.77) were more likely to contract COPD.
Conclusions We concluded that psoriasis patients were at a greater risk of developing COPD with significantly lower COPD-free survival rates than the comparison cohort (P < 0.001). Physicians should be aware of this potential risk to reduce comorbidity and mortality.